ADMA Biologics Inc (ADMA) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of ADMA Biologics Inc stock $14.08, price $12.73, upside +10.6%, quality 68 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range $1.09 – $24.51 · fair‑value band $8.99 – $21.01 · the $12.73 price screens below the $14.08 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow ADMA Biologics in your weekly email
Every Wednesday you see whether ADMA Biologics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
Show moreShow less
The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin.
In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Stock analysis
ADMA Biologics Inc (ADMA) currently trades at $12.73, while our model-based Fair Value estimate is $14.08, so the stock looks roughly fairly valued today (gap 9.6%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $30.48 per share, and 11 of the 24 models we run sit above the $12.73 price.
Bear case: the Asset-Based group reads lowest at $1.43, and 13 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $8.99 (bear) to $21.01 (bull), the price of $12.73 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
ADMA Biologics Inc reported revenue of $510M in FY2025 versus $80.9M in FY2021, a compound +58.4%/yr. Reported net income was $147M in FY2025.
Key figures
Market cap $2.9B Mid · P/E ratio 18.2 · P/S ratio 5.72 · EPS (TTM) $0.7000 · Net margin 33.0% · Return on equity 41.9% · Return on assets (EBIT) 6.7% (5-year average) · Operating margin 42.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 90 out of 100 (low confidence).
What moves the price
The share trades about 38% below its 52-week high and 68% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 11%, ADMA screens cheaper than that median.
Fair Value models
Bear$8.99Fair Value $14.08Bull$21.01
Price $12.73 · Upside +10.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.6003 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, one officer or director bought shares worth $250,874, on May 27, 2026. Over the same period, one person sold shares worth $1.8M.
SaleAdam S GrossmanPresident and CEO, Director5× since Nov 19, 2025: 231,000 shares, avg. $13.73$3.2MNov 5, 202610b5-1 plan
BuyJerrold B GrossmanDirector3× since May 11, 2026: 31,400 shares, avg. $7.99$250,874May 27, 2026
SaleKaitlin M. Kestenberg-MessinaCOO and SVP, Compliance10,096 shares at $15.63$157,800Mar 9, 2026
BuySteve ElmsDirector14,000 shares at $15.53$217,420Mar 6, 2026
Plus 3 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+19.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+49.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+64.6%
Start year 2020 (pandemic). Over 10 years: +53.2% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+60.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−153.8% (2020) → 37.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+39.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+12.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +35.9% a year for the price and +10.0% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (85 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
AI conclusion: The company's main strength is its validated proprietary IVIG manufacturing process with clear safety and purity advantages, while its main weak point is thin public data on moat factors combined with lingering questions over revenue practices.
Main risk: Lingering concerns from the short-seller report on revenue practices pose the biggest risk to rebuilding investor confidence and sustaining partnerships in its plasma-derived biologics business.
ADMA's shares sit well below their recent peak after a short-seller report in March raised questions about revenue practices. Recent peer-reviewed data now validates the safety and purity advantages of its proprietary IVIG manufacturing process. The open question is whether this technical edge can rebuild lasting investor confidence or whether lingering concerns from the earlier scrutiny will continue to weigh on the business. Does the validated process outweigh the past allegations in shaping future prospects?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside+10.6% · Top 25%
Profitability
Return on equity (12 months)41.9% · Top 25%
Return on assets23.5% · Top 25%
Net margin (12 months)33.0% · Top 25%
Operating margin (12 months)42.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)2.0% · Above median
Balance sheet
Debt / equity0.15× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is ADMA Biologics Inc (ADMA) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $14.08 versus a price of $12.73, about +11% upside (fairly valued).
What is the fair value of ADMA?
Our model-based fair value for ADMA Biologics Inc is $14.08 (as of Nov 8, 2026), built from audited fundamentals. The current price: $12.73.
What is the quality score of ADMA?
ADMA Biologics Inc has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ADMA Biologics Inc (ADMA)?
Our model-based price target is the fair value of $14.08 (as of Nov 8, 2026) from 24 valuation models. Cautious scenario $8.99, optimistic scenario $21.01. It is a calculation from audited fundamentals, not an analyst target.
What is the ADMA Biologics Inc stock forecast for 2026?
Our models put fair value at $14.08, about +11% upside versus a price of $12.73 (fairly valued). Cautious scenario $8.99, optimistic scenario $21.01. The calculation is refreshed regularly with new filings.
What is the revenue of ADMA Biologics Inc (ADMA)?
ADMA Biologics Inc reported trailing-twelve-month revenue of about $512M (latest available figure, as of Nov 8, 2026).
What growth is priced into ADMA Biologics Inc (ADMA)?
For today's price to be fair in a discounted-cash-flow model, ADMA Biologics Inc would have to grow free cash flow by +39.1 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +64.6 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of ADMA use?
Our models discount ADMA Biologics Inc at 8.9 %: a base by market capitalisation (mid), damped by beta 0.66, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ADMA Biologics Inc that is +39.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has ADMA Biologics Inc (ADMA) delivered so far?
Over the past 5 years revenue at ADMA Biologics Inc grew +64.6 % a year. The price currently implies free-cash-flow growth of +39.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of ADMA Biologics Inc (ADMA) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into ADMA Biologics Inc (+39.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of ADMA Biologics Inc (ADMA)?
The free-cash-flow yield on the price is 0.95 %: that much free cash flow ADMA Biologics Inc produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of ADMA Biologics Inc (ADMA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ADMA Biologics Inc it is $14.08 per share (as of Nov 8, 2026), against a price of $12.73. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is ADMA Biologics Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, ADMA trades below its calculated fair value: price $12.73, fair value $14.08, a gap of about +11% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ADMA?
No. The price is what the market pays today ($12.73); the fair value is what the company's own numbers justify ($14.08). For ADMA Biologics Inc the two are $1.35 per share apart. That gap is exactly why we show both numbers side by side.
How much is ADMA Biologics Inc worth?
The market values ADMA Biologics Inc at about $2.9B (market capitalisation, as of Nov 8, 2026). Per share that is $12.73; our models calculate a fair value of $14.08 per share.
What do the bullish and bearish scenarios say about ADMA?
Our models span a range for ADMA Biologics Inc: cautious scenario $8.99, base $14.08, optimistic $21.01 per share (as of Nov 8, 2026, price $12.73). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ADMA?
ADMA Biologics Inc trades at a price-to-earnings ratio of 18.2 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $14.08 is built from several models across several years. Other multiples: P/B 6.1, P/S 5.7, EV/EBITDA 13.0.
How solid is the balance sheet of ADMA Biologics Inc (ADMA)?
Balance-sheet figures for ADMA Biologics Inc (as of Nov 8, 2026): return on equity 41.9%, debt of 0.15 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is ADMA from its 52-week high?
ADMA Biologics Inc trades at $12.73, about 38% below its 52-week high of $20.38 and 68% above the low of $7.60 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $14.08 is for.
Which stocks are comparable to ADMA Biologics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ADMA Biologics Inc stock attractive at the current price?
The data as of Nov 8, 2026: price $12.73, calculated fair value $14.08 (+11%), Quality Score 68/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ADMA calculated?
We run ADMA Biologics Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $14.08 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. ADMA Biologics Inc currently trades 10% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ADMA Biologics Inc (ADMA)?
The closing price on Nov 6, 2026 was $12.73. Our model-based fair value is $14.08, about +11% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ADMA Biologics Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($8.99 to $21.01) leaves room in how you read the outcome.
Key figures of ADMA Biologics Inc
How large is the market capitalisation of ADMA Biologics Inc (ADMA)?
The market capitalisation of ADMA Biologics Inc is $2.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ADMA Biologics Inc (ADMA)?
The price-to-sales ratio of ADMA Biologics Inc is 5.72 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ADMA Biologics Inc (ADMA)?
Earnings per share at ADMA Biologics Inc are $0.7000 (price ÷ EPS = P/E 18.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of ADMA Biologics Inc (ADMA)?
The net margin of ADMA Biologics Inc is 33.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ADMA Biologics Inc (ADMA)?
The return on equity (ROE) of ADMA Biologics Inc is 41.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ADMA Biologics Inc (ADMA)?
On an EBIT basis the return on assets of ADMA Biologics Inc is 6.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ADMA Biologics Inc (ADMA)?
The operating margin of ADMA Biologics Inc is 42.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ADMA Biologics Inc (ADMA)?
Revenue at ADMA Biologics Inc is growing +2.0% versus a year earlier (3y avg +49.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ADMA Biologics Inc (ADMA)?
Earnings per share at ADMA Biologics Inc are growing +14.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does ADMA Biologics Inc (ADMA) hold?
ADMA Biologics Inc holds more cash than debt, $7.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch ADMA Biologics Inc in the live analysis
One click puts ADMA Biologics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 8, 2026